Zhonghua yi xue za zhi最新文献

{"title":"[Effect of SMARCA4 mutations on the outcomes of patients with advanced EGFR mutant lung adenocarcinoma].","authors":"X Liang, Y Q Jiang, X Y Liu, J L Xu, J Li, R H Guo","doi":"10.3760/cma.j.cn112137-20240904-02043","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240904-02043","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the impact of SMARCA4 mutations on the outcomes of patients with advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <b>Methods:</b> In the Memorial Sloan Kettering Cancer Center (MSK) MetTropism study, 960 patients with advanced EGFR-mutated lung adenocarcinoma were screened and included in the MSK cohort, composing of 313 males and 647 females, with a median [<i>M</i>(<i>Q</i>₁, <i>Q</i>₃)] age of 64 (56, 72) years. A retrospective analysis was conducted on the data of 178 patients with advanced EGFR-mutated lung adenocarcinoma who received EGFR tyrosine kinase inhibitors (TKIs) treatment in the Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, from January 2018 to December 2022. Among these patients, 69 were males and 109 were females, with a median age of 63 (54, 69) years. The follow-up of patients from the First Affiliated Hospital of Nanjing Medical University was conducted up to December 31, 2023, with a median follow-up time of 26.6 (95%<i>CI</i>: 24.6-28.6) months for the entire cohort, and 29 patients were lost to follow-up. Survival curves were plotted using the Kaplan-Meier method, and the log-rank test was used to compare the relationship between SMARCA4 gene alternations and prognosis. <b>Results:</b> In the 960 patients of the MSK cohort with advanced EGFR-mutated lung adenocarcinoma, the SMARCA4 gene alternations rate was 4.2% (40/960). The median overall survival (OS) for patients without SMARCA4 gene alternations was 41.5 (95%<i>CI</i>: 35.6-47.3) months, which was superior to that of patients with SMARCA4 gene alternations [15.6 (95%<i>CI</i>: 7.9-23.4) months, <i>P</i><0.001]. Patients with SMARCA4 gene alternations had a higher risk of mortality, with an <i>HR</i> (95%<i>CI</i>) of 1.97 (1.35 to 2.88). Among the 178 patients with advanced EGFR-mutated lung adenocarcinoma from the First Affiliated Hospital of Nanjing Medical University, the SMARCA4 gene alternations rate was 4.5% (8/178). The median progression-free survival (PFS) for patients without SMARCA4 gene alternations was 16.1 (95%<i>CI</i>: 12.2-20.0) months, which was superior to the median PFS of patients with SMARCA4 gene alternations [6.0 (95%<i>CI</i>: 1.3-10.7) months, <i>P</i><0.001]. The median OS for patients without SMARCA4 gene alternations was 50.1 (95%<i>CI</i>: 28.1-72.1) months, which was also superior to the median OS of patients with SMARCA4 gene alternations [17.6 (95%<i>CI</i>: 15.4-19.8) months, <i>P</i>=0.001]. <b>Conclusion:</b> SMARCA4 alternation is an important factor associated with poor prognosis in patients with advanced EGFR-mutant lung adenocarcinoma.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 4","pages":"306-311"},"PeriodicalIF":0.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Epidemiological characteristics and surgical treatment of inpatients with superficial hemangioma in Shandong province from 2019 to 2020].","authors":"M L Xu, B Y Zhang, X L Guo, R Huo","doi":"10.3760/cma.j.cn112137-20241205-02747","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20241205-02747","url":null,"abstract":"<p><p>The epidemiological characteristics and surgical treatment of inpatients with superficial hemangioma in Shandong province were investigated and analyzed. The first-page medical records of hospitalized patients with superficial hemangioma from 2019 to 2020 reported by all secondary and above medical institutions in Shandong province were selected from the National Health Information Platform of Shandong province to analyze their population characteristics and surgical treatment. A total of 3 775 patients with superficial hemangioma were included, with the age of [<i>M</i>(<i>Q</i>₁, <i>Q</i>₃)] 3.0(0, 33.0)years, including 1 419 males (37.6%) and 2 356 females (62.4%). The head and neck superficial hemangioma accounted for the highest proportion of 37.8% (1 425/3 775), followed by limbs 34.5% (1 302/3 775) and trunk 24.4% (922/3 775). Infants accounted for the highest proportion of 37.2% (1 406/3 775). There were 2 874 (76.1%) patients with superficial hemangioma received surgical treatment, and the proportion of male patients receiving surgery was higher than that of female patients[78.2%(1 110/1 419) vs 74.9%(1 764/2 356), <i>P</i>=0.019]. The proportion of patients receiving surgery increased with age (<i>P</i>_trend<i><</i>0.001). In terms of different parts, the proportion of patients with superficial hemangioma in the limbs who received surgery was the highest at 86.2%(1 123/1 302) (<i>P</i><0.001). The majority of the surgical operations were secondary surgery (55.8%, 1 110/1 988), elective surgery (91.4%, 1 818/1 988), class Ⅰ incision (53.5%, 1 338/2 501), and general anesthesia (50.9%, 1 219/2 397). The main treatment method was resection (48.1%, 1 816/3 775). The study found that the majority of inpatients with superficial hemangioma in Shandong province were mostly in head and neck, with more females than males, and infants being the main group, and surgical treatment was the main treatment.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"240-243"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on neuropsychological assessment for mild cognitive impairment (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20240612-01322","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240612-01322","url":null,"abstract":"<p><p>Mild cognitive impairment (MCI) is a state of objective cognitive decline that falls between normal aging and dementia, with a high prevalence among the elderly in China. Cognitive impairments in MCI patients involve multiple cognitive domains such as memory, language, attention, executive, visuospatial functions, and social cognition, as well as non-cognitive domains such as neuropsychiatric, mood, sleep, daily living activities, and frailty. The assessment and clinical diagnosis of MCI highly rely on neuropsychological testing. In order to standardize the neuropsychological assessment of MCI, the Dementia and Cognitive Disorders Group of the Chinese Society of Neurology formulated this consensus document. It recommends tools for assessing global cognition, various cognitive domains, and non-cognitive functions suitable for both clinical and research settings. The consensus proposes assessment procedures and precautions based on the experiences of domestic researchers. Based on the latest international and domestic research advancements, using the Delphi method and the GRADE evidence system, 24 recommendations were formulated in 5 aspects of MCI: global cognitive function assessment, various cognitive domains assessment, non-cognitive assessment, the use of neuropsychological scales, and precautions in neuropsychological assessment, aiming to improve the diagnosis and management of MCI in China.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"204-218"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of etiology and short-term prognosis of childhood arterial ischemic stroke based on the COIST classification].","authors":"Z M Yu, J J Jia, J W Li, L B Meng, J Zhou, W H Zhang, H Xiong, F Fang, X W Zhuo","doi":"10.3760/cma.j.cn112137-20240422-00948","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240422-00948","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; This study aims to analyze the etiology and short-term prognosis of childhood arterial ischemic stroke (AIS) in Chinese children, based on the COIST classification system. &lt;b&gt;Methods:&lt;/b&gt; A total of 380 pediatric patients with a first-ever diagnosis of AIS treated at Beijing Children's Hospital between September 2015 and April 2024 were retrospectively included. Etiology was analyzed according to COIST classification. The patients were categorized into infant and toddler group with 117 cases (&gt;28 days to≤3 years), preschool group with 90 cases (&gt;3 years to≤7 years), school-age group with 90 cases (&gt;7 years to≤11 years), and adolescent group with 83 cases (&gt;11 years to≤18 years). The etiological distribution across age groups and the short-term prognosis of patients with different etiologies were further analyzed. &lt;b&gt;Results:&lt;/b&gt; Among the 380 patients, 235 were male (61.8%) and 145 were female (38.2%), with a mean age at presentation of(6.6±4.6)years. Approximately 2/3 of the patients were admitted in the Department of Neurology, with a mean hospital stay of (13.2±6.7)days. (1) Etiological analysis: \"Vascular structural abnormalities\" were the most common cause, accounting for 38.2% (145/380), followed by \"Inflammatory\" causes at 31.1% (118/380), \"Undetermined\" at 11.1% (42/380), \"Other identifiable causes\" at 9.2% (35/380), \"Cardiac diseases\" at 6.3% (24/380), and \"thrombophilia\" at 4.2% (16/380). (2) Etiological distribution by age group: in the infant and toddler group, \"vascular structural abnormalities\" were 47.9% (56/117), with basal ganglia infarction following minor trauma(combined with basal ganglia calcification) being the most common (40/117). In the preschool group, there were 34 cases (34/90) of \"inflammatory\" and 33 cases (33/90) of \"vascular structural abnormalities\", with Moyamoya disease being the most frequent cause (15/90). In the school-age group, there were 37(37/90) cases of \"vascular structural abnormalities\", with arterial dissection (12/90)being the most common, followed by FCA-i (11/90), and Moyamoya disease (11/90). In the adolescent group, there were 34 cases of \"inflammatory\"(34/83), with the highest proportion of FCA-i (13/83) in the subgroup, followed by thrombophilia (9/83) and systemic lupus erythematosus (8/83). (3) Short-term prognosis: based on the PSOM scale, 188 cases had good prognosis, accounting for 49.5% (188/380), while 192 cases had poor prognosis, accounting for 50.5% (192/380). According to the mRS score, 207 cases had good prognosis (54.5%) and 173 cases had poor prognosis (45.5%). Subtypes such as \"Inflammatory-noninfectious, \" FCA-i, Moyamoya disease, and arterial dissection were associated with relatively better outcomes. Less than 1/3 of patients in the \"other identifiable causes\" group had favorable prognosis. The in-hospital mortality rate was 3.7% (14/380). &lt;b&gt;Conclusions:&lt;/b&gt; Vascular structural abnormalities and inflammatory (including infectious and non-infectious) f","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"225-232"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Guideline for diagnosis and treatment of sarcopenia in China (2024 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20240724-01701","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240724-01701","url":null,"abstract":"<p><p>Sarcopenia, an aging-related geriatric syndrome, is characterized by decreased muscle mass, declined muscle strength, and/or physical dysfunction. It is associated with significantly increased risks of falls, frailty, disability, and even death, placing a heavy burden on individuals and society. Standardized diagnosis and treatment of sarcopenia are of paramount importance for clinical practice and the development of healthy aging in China. However, to date, there is a lack of evidence-based clinical practice guideline for the diagnosis and treatment therapy of sarcopenia in China. Therefore, the National Clinical Research Center for Geriatric Diseases (Xiangya Hospital) has initiated the development of this guideline for sarcopenia, with the approval of Geriatrics Branch of the Chinese Medical Association. Development of this guideline adhered to the Guiding principles for development/revision of clinical practice guidelines in China (2022 version) and the Reporting Items for Practice Guidelines in Healthcare (RIGHT). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to assess the strength of evidence. The Delphi technique was used to determine the strength of recommendations. Finally, a total of 18 evidence-based recommendations for the diagnosis and treatment of sarcopenia were formulated in response to 12 most concerned important clinical questions about sarcopenia. This guideline aims to enhance the scientific approach to sarcopenia diagnosis and treatment in China, promote the in-depth development of sarcopenia research, and ultimately improve the quality of patient-centered healthcare services.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"181-203"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparative analysis of the efficacy of domestic and imported sugammadex for reversal of rocuronium-induced deep neuromuscular block in adult patients].","authors":"X Y Yang, Z Y Geng, D X Wang, X M Wu, X Y Li","doi":"10.3760/cma.j.cn112137-20240725-01713","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240725-01713","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy of domestic and imported sugammadex for reversal of rocuronium-induced deep neuromuscular block (NMB) in adult patients. <b>Methods:</b> The clinical data of adult patients who scheduled for elective surgery with general anesthesia that required muscle relaxants in Peking University First Hospital from June 2023 to June 2024 were prospectively included. The patients were devided into domestic group and imported group according to random number table method. Anesthetized patients received rocuronium for intubation and muscle relaxation, and anesthesia was maintained with propofol, sevoflurane, and remifentanil. The effect of neuromuscular block was monitored. During deep muscle relaxation (with a single stimulation muscle twitch count of 1-2 after tetanic stimulation), domestic and imported sugammadex 4 mg/kg was given, respectively. The primary outcome was the recovery time from sugammadex injection to return of the train-of-four ratio (TOFr) to 0.9, with a non-inferiority margin of 1 minute (the range of non-inferiority boundary value is ±1 minute). The secondary outcome included the ratios of TOFr to 0.9 at different times and adverse effects. <b>Results:</b> A total of 70 patients were included, including 35 patients in the domestic group (13 males and 22 females), aged (46.9±12.7) years, and 35 patients in the imported group (13 males and 22 females), aged (45.7±11.5) years. There was no statistically significant difference in demographic characteristics, surgical time, anesthesia time, total rocuronium dose, and extubation time between two groups. All patients recovered to a TOFr of 0.9 within 5 minutes. Reversal time was 1.8 (1.3, 2.6) minutes in the domestic sugammadex group and 2.0 (1.7, 2.9) minutes in the imported sugammadex group respectively. The difference in reversal times between two groups was -0.40 minutes (95%<i>CI</i>:-0.75 to -0.02, <i>P</i>=0.039), which was within the range of non-inferiority threshold. Within 5 minutes of administration of antagonists, the incidence of bradycardia was 14% (5/35 and 5/35) in both domestic and imported groups. The incidence of skin allergy in patients transported to the post-anesthesia recovery room (PACU) was 3% (3/35) and 0 in both groups, respectively, with no statistical significance (all <i>P</i>>0.05). There were no serious drug-related adverse events in both groups. <b>Conclusion:</b> The effect of domestic sugammadex is not inferior to imported sugammadex in reversal of deep rocuronium-induced neuromuscular block in adult patients, and the incidence of postoperative adverse events is not increased.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"233-239"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of ten-eleven translocation methylcytosine dioxygenase 2 gene mutations on the secondary myelofibrosis of JAK2^V617F positive myeloproliferative neoplasms patients].","authors":"Y Wang, Y H Zhang, G S Teng, C X Du, H Q Zhang, Y F Duan, X J Wei, J Y Ma, Y Zhou, W P Yuan, Z H Shao, J Bai","doi":"10.3760/cma.j.cn112137-20240905-02056","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240905-02056","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect of ten-eleven translocation methylcytosine dioxygenase 2 (TET2) gene mutations on the secondary myelofibrosis (SMF) of JAK2^V617F+ myeloproliferative neoplasms (MPN) patients. <b>Method:</b> A retrospective collection was conducted on MPN patients with JAK2^V617F mutation detected by second-generation sequencing in the Department of Hematology, the Second Hospital of Tianjin Medical University. TET2⁺JAK2^V617F+ MPN patients were selected as the mutant group, and TET2^-JAK2^V617F+ MPN patients matched for age and gender were selected as the non-mutant group. The differences in mortality and SMF between the two groups were followed up until November 11, 2022. The second-generation sequencing technology was used to detect 325 mutated genes in hematological malignancies, in order to determine the differences between two groups of mutated genes. Enzyme linked immunosorbent assay (ELISA) was used to detect and compare the levels of cytokines such as transforming growth factor (TGF)-β1, interleukin (IL)-17, interferon (IFN)-γ in the bone marrow supernatant of the both groups. Multivariate Cox regression analysis was used to investigate the influencing factors of SMF in JAK2^V617F+ MPN patients. <b>Result:</b> A total of 96 patients were included, with 32 in the mutant group, including 16 males and 16 females, aged [<i>M</i> (<i>Q</i>₁, <i>Q</i>₃)] 61 (53, 70) years, and 64 in the non-mutant group, including 32 males and 32 females, aged 58 (51, 68) years. After a follow-up of 61(43, 116) months, the mortality rate of patients in the mutant group [15.6% (5/32) vs 1.6% (1/64), <i>P</i>=0.007] and the proportion of SMF [43.8% (14/32) vs 14.1% (9/64), <i>P</i>=0.001] were higher than those in the non-mutant group. The proportion of FAT1 [25.0% (8/32) vs 7.8% (5/64), <i>P</i>=0.028], U2AF1 [15.6% (5/32) vs 0, <i>P</i>=0.003], and KMT2D [15.6% (5/32) vs 3.1% (2/64), <i>P</i>=0.039] gene mutations in the mutant group was higher than that in the non-mutant group. The mutant group had higher levels of TGF-β1 [13 837(8 298, 17 509) vs 7 915 (3 586, 10 545) ng/L, <i>P</i>=0.016], IL-17 [7.4 (6.3, 7.5) vs 6.1 (5.9, 7.1) ng/L, <i>P</i>=0.007], and IFN-γ[8.5 (8.1, 9.1) vs 8.0 (7.5, 8.3) ng/L, <i>P</i>=0.007] compared to the non-mutant group. The results of multivariate Cox regression analysis showed that TET2 mutation (<i>HR</i>=8.483, 95%<i>CI</i>: 1.278-56.330) was a risk factor of SMF in JAK2^V617F+ MPN patients. <b>Conclusion:</b> TET2 mutation is a risk factor for SMF in JAK2^V617F+ MPN patients.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 3","pages":"219-224"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical practice guidelines for perioperative fluid therapy in Chinese adult patients (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20241003-02245","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20241003-02245","url":null,"abstract":"<p><p>Perioperative fluid therapy is a pivotal component of surgical patient management, as appropriate fluid administration can significantly enhance postoperative recovery. To standardize perioperative fluid therapy for adult patients in China, the Geriatric Anesthesia and Perioperative Management Group of the Chinese Society of Anesthesiology has developed the \"Clinical Practice Guidelines for Perioperative Fluid Therapy in Chinese Adult Patients\". Based on current clinical status in China, this guideline addressed 11 key areas based on clinical evidence, more than 30% of which is from China researchers, including principles for the selection of common fluid types, preoperative fasting and hydration following enhanced recovery after surgery (ERAS) protocols, intraoperative fluid requirements for adult patients, perioperative volume assessment, perioperative evaluation of volume overload/insufficiency, goal-directed fluid therapy, restrictive fluid therapy, perioperative fluid therapy strategies for high-risk patients, fluid resuscitation for massive blood loss, the relationship between perioperative fluid therapy and postoperative complications, and the relationship between perioperative fluid therapy and ERAS. The guideline included 51 evidence-based recommendations aimed at optimizing perioperative fluid management and improving patient outcomes after surgery.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 2","pages":"128-154"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Current situation, challenges and suggestions for influenza vaccination among the elderly in China].","authors":"M M Jia, L Z Feng","doi":"10.3760/cma.j.cn112137-20240826-01962","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20240826-01962","url":null,"abstract":"<p><p>The elderly population in China faces a significant burden of influenza, but the influenza vaccination rate among this group remains far below international recommended standards due to factors such as the underdeveloped adult immunization service system, high vaccination costs, and insufficient awareness among both the elderly and healthcare professionals. It is recommended that China implement a free or reimbursement policy influenza vaccination for elderly in border regions, improve the adult immunization service system, enhance the awareness of healthcare professionals and the elderly, and strengthen the research and post-vaccination monitoring of vaccines tailored to the elderly population to increase the influenza vaccination rate among the elderly.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 2","pages":"123-127"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Boosting the innovation transformation of clinical medicine based on core technology in anesthesiology].","authors":"T L Wang, W F Yu, Y M Zeng","doi":"10.3760/cma.j.cn112137-20241125-02642","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20241125-02642","url":null,"abstract":"<p><p>The core technologies proposed in surgery have boosted the innovation transformation and disciplinary development. However, the core technologies in anesthesiology remain undefined both domestically and internationally. Through collaborative discussions among Chinese anesthesiologists, the core technologies of anesthesiology can be succinctly summarized as Relief of pain, Regulation of life, Resuscitation, and Restoration of organ function, and collectively referred to as the 4R technologies. Their primary components include: (1) Technology for sedation, analgesia and muscle relaxation; (2) Technology for the monitoring and regulation of life; (3) Technology for resuscitation and restoration of organ function; (4) Technology for diagnosis and therapy for acute and chronic pain, as well as functional regulation. Up to now, there is still a significant gap between the current situation of anesthesiology and the requirements of core technologic content. Exclusive innovation transformation can remodel the new future of anesthesiology.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 2","pages":"97-100"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}